Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Poxel : 1H 2020 Financial and Corporate Presentation

share with twitter share with LinkedIn share with facebook
09/15/2020 | 12:51pm EDT

First Half 2020

Financial and Corporate Update

September 15, 2020

1

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not

historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of

forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or

similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions,

estimates and projections. Investors should therefore not place undue reliance on those statements. The Company

makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be

achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should

not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they

are made and the Company does not undertake to update any forward-looking statements in light of new information or

future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number

of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on

March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business. As of the date of this

presentation, and based on publicly available information, the Company has not identified the occurrence of any material

negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company

anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The

worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in

countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19

may impact market conditions and the Company's ability to seek additional funding or enter into partnerships.

Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical

and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could

potentially have an impact on the Company's development programs and partnered programs. The Company will

2

continue to actively monitor the situation.

1H 2020: Significant R&D and Corporate Accomplishments

1

2

3

4

5

6

7

3

Imeglimin for Type 2 Diabetes (T2D)

  • Japanese New Drug Application submission by Sumitomo; product launch targeted for 2021*
  • Metavant regulatory discussions for Ph 3 program in patients with T2D and CKD stages 3b/4

PXL770 for NASH

  • Positive PK/PD results; trial met primary endpoint and objectives
  • Presented new preclinical results related to improvement in inflammation
  • Ph 2a efficacy & safety results in ~100 patients expected around the end of September 2020

PXL065 for NASH

  • Initiation of Ph 2 efficacy and safety study in ~120 biopsy-proven patients; goal to identify optimal dose or doses for Ph 3 registration trial
  • Streamlined development with single Ph 2 trial given knowledge of pioglitazone, including data in NASH, and 505(b)(2) regulatory pathway, which offers opportunity for efficient and lower risk program

Preclinical NASH Combination Results

  • Positive results for PXL770 combinations with FXR agonist (obeticholic acid), a GLP-1 receptor agonist (semaglutide) and a thyroid receptor β agonist (MGL-3196)

Preclinical AMPK Platform Results

  • Positive results for PXL770 and AMPK activation in chronic and rare metabolic diseases
    Strengthened Financial Position with Multiple Sources (EUR 31.7M)
  • Drew down second tranche of IPF loan of EUR 10M and capital raise of EUR 17.7M (1H 2020)
  • Sumitomo milestone triggered EUR 4M for J-NDA submission (Q3 2020)

Expanded Management Team

Appointed David E. Moller, MD, as CSO

* Year noted is Fiscal Year from April 2021 to March 2022, which is Sumitomo Dainippon Pharma's Fiscal Year.

Financial Update

First Half 2020

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Poxel SA published this content on 15 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2020 15:49:06 UTC


share with twitter share with LinkedIn share with facebook
All news about POXEL
10/28Poxel Announces Participation at Several Upcoming Scientific and Investor Con..
AQ
10/27POXEL : Announces Participation at Several Upcoming Scientific and Investor Conf..
BU
10/21Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
AQ
10/20POXEL : Corporate Presentation - English
PU
10/20POXEL : Provides Corporate Update and Reports Cash and Revenue for the Third Qua..
BU
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
10/15POXEL : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French..
BU
10/11POXEL : Corporate Presentation - English
PU
10/07POXEL : Corporate Presentation - English
PU
10/02POXEL : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Oral..
AQ
More news
Financials
Sales 2020 14,7 M 17,2 M 17,2 M
Net income 2020 -28,0 M -32,7 M -32,7 M
Net cash 2020 21,6 M 25,2 M 25,2 M
P/E ratio 2020 -5,63x
Yield 2020 -
Capitalization 167 M 195 M 195 M
EV / Sales 2020 9,88x
EV / Sales 2021 2,40x
Nbr of Employees 51
Free-Float 75,3%
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 18,55 €
Last Close Price 5,87 €
Spread / Highest target 258%
Spread / Average Target 216%
Spread / Lowest Target 181%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-51.89%195
GILEAD SCIENCES, INC.-9.93%73 380
REGENERON PHARMACEUTICALS48.02%58 486
VERTEX PHARMACEUTICALS-5.45%53 919
WUXI APPTEC CO., LTD.71.35%40 739
BEIGENE, LTD.80.68%27 143